Skip to main content

Ingrid Jyssum

PhD fellow
https://orcid.org/0000-0003-1412-9713
See Google Scholar profile
See publications in PubMed

Education

  • Doctor (MD) at the Faculty of Medicine, University of Oslo

Position

  • PhD fellow, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet Hospital

Field of interest

  • Rheumatology
  • Immunosuppressive medications
  • Personalized medicine
  • Therapeutic drug monitoring
  • Vaccines
  • Randomized controlled trials

Email

This email address is protected from programs that collect email addresses. You need JavaScript enabled to view it.

Telephone

+47 22451500

visiting address

Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP6 - Dechiphering long-term outcomes

NOR-DMARD

The Norwegian register for antirheumatic drugs

Project Manager:
Tore K. Kvien
WP2 - PPhenotyping for personalized medicine

Nor-vaC

Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment

Project Manager:
Guro Løvik Goll
WP1 - Optimized medical interventions

RA DRUM

Therapeutic drug monitoring in patients with rheumatoid arthritis (RA-DRUM)

Project Manager:
Silje Watterdal Syversen
WP1 - Optimized medical interventions

SQUEEZE

Maximizing the effect of prescription drugs in rheumatoid arthritis 

Project Manager:
Espen A. Haavardsholm

Publications

Publications taken from the National Science Archive (NVA):

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Hassen Kared, Ingrid Jyssum, Amin Alirezaylavasani, Ingrid Marie Egner, Trung The Tran, Lisa Tietze


Frontiers in Immunology

2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Hilde Sofie Sager Ørbo, Kristin Reine Hammersbøen, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen


RMD Open

2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

Asia-Sophia Fumika Michaela Wolf, Kristin Reine Hammersbøen, Hilde Sofie Sager Ørbo, Sabin Bhandari, Guri Solum, Ingrid Fadum Kjønstad


EBioMedicine

2024

Therapeutic serum level for adalimumab in rheumatoid arthritis: exploratory analyzes of data from a randomized phase III trial

Johanna Gehin, Rolf Klaasen, Eirik Kristianslund, Ingrid Jyssum, Joseph Sexton, David Warren


RMD Open

2024

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Ingrid Jyssum, Johanna Gehin, Joseph Sexton, Eirik Kristianslund, Yi Hu, David Warren


Rheumatology

2023

Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

Kristin Kaasen Jørgensen, Marte Lie Høivik, Adity Chopra, Jurate Saltyte Benth, Petr Ricanek, Bjørn Allan Moum


Scandinavian Journal of Gastroenterology

2023

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

Kristin H. Bjørlykke, Hilde Sofie Sager Ørbo, Anne Therese Tveter, Ingrid Jyssum, Joseph Sexton, Trung Tran


The Lancet Rheumatology

2022

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Ingrid Egeland Christensen, Trung Tran


RMD Open

2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Ingrid Egeland Christensen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Trung Tran, Siri Mjaaland


BMC Medicine

2022

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Trung Tran, Joseph Sexton, Sella Aarrestad Provan


Arthritis & Rheumatology

2022

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Ingrid Jyssum, Hassen Kared, Trung Tran, Anne Therese Tveter, Sella Aarrestad Provan, Joseph Sexton


The Lancet Rheumatology

2021